Transfusion and Apheresis Science
Volume 37, Issue 1 , Pages 37-41 , August 2007

Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?

  • Volker Diehl

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 221 478 86653; fax: +49 221 478 86654.
    • ,
  • Michael Fuchs
    • ,
  • On behalf of the German Hodgkin Lymphoma Study Group (GHSG)

Received 11 April 2007 ,Accepted 24 April 2007.

References 

  1. DeVita VT, Carbone PP. Treatment of Hodgkin’s disease. Med Ann Dist Columbia. 1967;36:232–234passim
  2. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–259
  3. Jones SE, Haut A, Weick JK, Wilson HE, Grozea P, Fabian CJ, et al. Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin’s disease: a Southwest oncology group study. Cancer. 1983;51:1339–1347
  4. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol. 1996;14:1421–1430
  5. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998;16:19–26
  6. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21:607–614
  7. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630–637
  8. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate – and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23:9198–9207
  9. Radford JA, Rohatiner AZ, Ryder WD, Deakin DP, Barbui T, Lucie NP, et al. J Clin Oncol. 2002;20:2988–2994
  10. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–2395
  11. Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. German Hodgkin’s lymphoma study group. Ann Oncol. 1996;7(Suppl. 4):95–98
  12. Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21:1734–1739
  13. Diehl V, Brillant C, Franklin J, Hermann R, Greil R, Engert A, et al. BEACOPP chemotherapy for advanced Hodgkin’s disease: results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG). Blood. 2004;104:307a
  14. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van ’t Veer MB, Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348:2396–2406

PII: S1473-0502(07)00093-6

doi: 10.1016/j.transci.2007.04.004

Transfusion and Apheresis Science
Volume 37, Issue 1 , Pages 37-41 , August 2007

Article Tools